NextBio

Help
Description: Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.
Drug Type: Small Molecule; Approved
Pharmacology: Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Mechanism of Action: Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Indication: For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Half Life: 5.9 days
View Complete Description



Data Correlations | 2 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
AR 100 100
KLK2 98 98
TRPM8 95 95
CCDC141 93 93
STEAP4 92 92
TRGC2 91 91
View Top Genes
Biogroups category icon Biogroups
Score Help
Zinc finger, NHR/GATA-type 100 100
TRKA Receptor Signaling Pathway 100 100
Phenylpropanoid Biosynthesis 99 99
Peptidase S1A, chymotrypsin 98 98
Immunoglobulin C1-set 97 97
Type II keratin 97 97
View Top Biogroups

Individual Studies

  • LNCaP treatment of cells with DHT and a sequence-specific DNA binding polyamide

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    Androgen Receptor (AR) is essential for the growth and progression of prostate cancer in both hormone-sensitive and hormone-refractory disease. We have designed a sequence-specific DNA binding polyamide (1) that targets the consensus androgen response element (ARE). This polyamide binds the PSA prom…

    Authors: Dervan PB, Nickols NG

    Organization: California Institute of Technology 1200 …

  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving bicalutamide.

View All Author iconAuthors
  • Mauro Bologna
  • Giovanni Luca Gravina
  • Claudio Festuccia
  • Carlo Vicentini
  • Paola Muzi
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • AstraZeneca
  • Memorial Sloan-Kettering Cancer Center
  • European Organization for Research and Treatment of Cancer
  • University of L'Aquila
  • Ferring Pharmaceuticals
View All Affiliations icon Organizations
  • University of L'Aquila
  • University of Tennessee Health Science Center
  • University of Tübingen
  • Beth Israel Deaconess Medical Center
  • Kyoto University Graduate School of Medicine

Clinical Trials | 344 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “bicalutamide”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “bicalutamide”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio